Results 191 to 200 of about 58,087 (312)

A Proposed Methodology to Select Radioisotopes for Use in Radionuclide Therapy [PDF]

, 2009
John Cuaron, Joshua A Hirsch, David Medich, Barry S. Rosenstein, Christopher B. Martel, Ariel E. Hirsch   +5 more
openalex   +1 more source

Case Series of Patients With FGFR1‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options

Clinical Endocrinology, Volume 102, Issue 6, Page 626-634, June 2025.
ABSTRACT Pheochromocytoma and paraganglioma (together PPGL) are tumours with a high degree of heritability. Genetic landscape is divided into three clusters, cluster 1 (Krebs/pseudohypoxia signalling pathway), cluster 2 (kinase signalling pathway) and cluster 3 (Wnt signalling pathway).
Sakshi Jhawar, Abhishek Jha, Sara Talvacchio, Junne Kamihara, Jaydira Del Rivero, Karel Pacak   +5 more
wiley   +1 more source

Relationship Between Best Tumor Shrinkage and Progression‐Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu‐DOTA‐TATE: Ad Hoc Analysis of the Phase III NETTER‐1 Trial

Cancer Medicine, Volume 14, Issue 9, May 2025.
We analyzed data from the phase III NETTER‐1 study of 177Lu‑DOTATATE for patients with advanced midgut neuroendocrine tumors to explore whether tumor shrinkage is associated with durable efficacy. Although patients receiving 177Lu‑DOTATATE had a progression‐free survival (PFS) benefit, no obvious association between best tumor shrinkage and PFS or ...
Marianne Pavel, Martyn E. Caplin, Philippe Ruszniewski, Marianna Hertelendi, Eric P. Krenning, Jonathan R. Strosberg, on behalf of the NETTER‐1 Study Group   +6 more
wiley   +1 more source

Comprehensive Whole‐Course Management Strategy for Recurrent Renal Cell Carcinoma: Case Report and Literature Review

Clinical Case Reports, Volume 13, Issue 5, May 2025.
ABSTRACT Renal cell carcinoma, a highly recurrent and metastatic malignancy. Drawing upon a decade‐long expertise in managing recurrent cases, we advocate the adoption of Programmed Death‐1 (PD‐1) inhibitors in conjunction with Axitinib when monotherapy with Axitinib fails to restrain tumor metastasis, thereby empowering doctors with an efficacious ...
PengNan Hu, Di Chen, Jun Yu, Hua Mi
wiley   +1 more source

Radiopharmaceuticals: From Molecular Imaging to Targeted Radionuclide Therapy

, 2004
P. August Schubiger, Jürgen Grünberg, Simon M. Ametamey, Michael Honer, Elisa García‐Garayoa, Peter Bläuenstein, Robert Waibel, Ilse Novak‐Hofer, Roger Schibli   +8 more
openalex   +2 more sources

Monitoring and Predicting Response to Peptide Receptor Radionuclide Therapy: A Quantitative SPECT-CT Based Analysis~!2009-12-10~!2010-02-04~!2010-04-21~! [PDF]

, 2010
Ponraj Chinnadurai, Scott Berg, Guillaume Nicolas, Martin A. Walter, Helmut Rasch, Jan Mueller‐Brand, Stefan Kneifel   +6 more
openalex   +1 more source

Analysis of carbohydrates and glycoconjugates by matrix‐assisted laser desorption/ionization mass spectrometry: An update for 2021–2022

Mass Spectrometry Reviews, Volume 44, Issue 3, Page 213-453, May/June 2025.
Abstract The use of matrix‐assisted laser desorption/ionization (MALDI) mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this review is the 12th update of the original article published in 1999 and brings coverage of the literature to the end of 2022.
David J. Harvey
wiley   +1 more source

Explanation of the Draft "Release of Patients after Therapy with Unsealed Radionuclides" of the International Commission on Radiological Protection: The 1st Report(Science Exchanges Committee Report)

, 2004
Hiroshi Watanabe
openalex   +2 more sources

The Third Pillar of Precision Medicine — Precision Delivery

MedComm, Volume 6, Issue 5, May 2025.
For Precision Medicine to reach its full potential, a third pillar called Precision Delivery is starting to evolve to complement the existing two pillars of Precision Diagnosis and Precision Therapy. Precision Delivery will help ensure the right therapy for the right disease will be able to reach the right location at the right time .
Avnesh S. Thakor
wiley   +1 more source

The Safety and Efficacy of Targeted Alpha Therapy, Ac‐225 Prostate‐Specific Membrane Antigen, in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Systematic Review and Meta‐Analysis

The Prostate, Volume 85, Issue 6, Page 541-557, May 2025.
ABSTRACT Background Metastatic castration resistance prostate cancer (mCRPC) is a challenging disease with a significant burden of mortality and morbidity. Most of the patients attain resistance to the available treatments, necessitating further novel therapies in this clinical setting.
Huseyin Besiroglu, Mustafa Kadihasanoglu
wiley   +1 more source